Actinogen Medical Limited
ATGGF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | 0.10 | -0.01 |
| FCF Yield | -10.09% | 184.25% | -20.34% | -12.61% |
| EV / EBITDA | -11.63 | 2.64 | -29.40 | -3.27 |
| Quality | ||||
| ROIC | -31.36% | -33.63% | -0.99% | -88.22% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 76.68% |
| Cash Conversion Ratio | 1.42 | -0.21 | 7.03 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 41.01% | 18.28% | 20.93% | 2.81% |
| Free Cash Flow Growth | -637.25% | 116.59% | -61.19% | -7.08% |
| Safety | ||||
| Net Debt / EBITDA | 1.94 | 2.75 | 6.34 | 0.93 |
| Interest Coverage | 0.00 | 0.00 | -106.08 | -1,029.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 95.03 | 0.00 | 94.02 | -764.89 |